Open Accessibility Menu
Hide

Breast Clinical Trials

Study Name: ALISCA-Breast1

  • Cancer Stage: IV
  • Key Inclusion: HR+/HER 2-
  • Description: A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  • Study Number: PUMA-ALI- 1201
  • NCT#: NCT06369285

Study Name: EvoPAR-BR01

  • Cancer Stage: IV
  • Key Inclusion: BRCA1, BRCA2, PALB2
  • Description: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/​6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/​ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
  • Study Number: D9722C00001
  • NCT#: NCT06380751

Study Name: Elaine III

  • Cancer Stage: IV
  • Key Inclusion: ESR1m, ER+/HER2
  • Description: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/​HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)
  • Study Number: SMX22-002
  • NCT#: NCT05696626

Study Name: (CAPItello-292)

  • Cancer Stage: IV
  • Key Inclusion: HR+/HER2-
  • Description: Capivasertib + CDK4/​6i + Fulvestrant for Advanced/​Metastatic HR+/​HER2- Breast Cancer (CAPItello-292)
  • Study Number: D361DC00001
  • NCT#: NCT04862663

Study Name: ASCENT-05

  • Cancer Stage: I-III
  • Key Inclusion: TNBC; Residual Disease
  • Description: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/​AFT-65 OptimICE-RD/​NSABP B-63).
  • Study Number: GS-US-595-6184
  • NCT#: NCT05633654

Study Name: OFSET

  • Cancer Stage: I-II
  • Key Inclusion: Oncotype 16-26
  • Description: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/​HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
  • Study Number: NRG-BR009
  • NCT#: NCT05879926

Study Name: pionERA

  • Cancer Stage: IV
  • Key Inclusion: ER+; HER2-
  • Description: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/​6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer).
  • Study Number: C044657
  • NCT#: NCT04576455

Study Name: CC011

  • Cancer Stage: I-III
  • Key Inclusion: Survivor
  • Description: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors.
  • Study Number: NRG-CC011
  • NCT#: NCT05896189

Study Name: OptimICE-PCR

  • Cancer Stage: I-II
  • Key Inclusion: CR TNBC Adjuvant
  • Description: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab.
  • Study Number: A012103
  • NCT#: NCT05812807

Study Name: Scarlet

  • Cancer Stage: N/A
  • Key Inclusion: N/A
  • Description: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
  • Study Number: S2212
  • NCT#: NCT05929768

For more information, call 240-566-4100

All Locations